AstraZeneca Gets EU Marketing Approvals for Cancer Drug

By Christian Moess Laursen

AstraZeneca said it has received two EU marketing approvals from the European Medicines Agency for cancer drug Dato-DXd jointly developed with Japan's Daiichi Sankyo.

The pharmaceutical giant said Monday that the EMA has granted marketing approval for Dato-DXd in the treatment of lung cancer and breast cancer.

Following the validations, the scientific review process by the EMA's Committee for Medicinal Products for Human Use will begin, AstraZeneca said.

"Today's dual validation of our applications in lung and breast cancers brings this potential medicine a meaningful step closer to redefining treatment expectations for patients with two of the most common cancers in Europe," Executive Vice President for oncology research and development, Susan Galbraith, said.

Dato-DXd, or Datopotamab deruxtecan, is a specifically engineered antibody drug conjugate, discovered by Daiichi Sankyo and jointly developed by AstraZeneca and Daiichi Sankyo.

Write to Christian Moess Laursen at [e-mail]

(END) Dow Jones Newswires

03-04-24 0235ET